Work

Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx376.003

Authors: R. Figlin, C. Nicolette, N. Tannir, S.S. Tykodi, D. Chen, V. Master, B. Lane, M. Debenedette, T. Monesmith, W. Tan, S. Leland, C.G. Wood

Institutions: Cedars-Sinai Medical Center, Argos Therapeutics (United States), The University of Texas MD Anderson Cancer Center, University of Washington, Fred Hutch Cancer Center, Fox Chase Cancer Center, Emory University, Spectrum Health, Corewell Health Blodgett Hospital

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2760819643

FWCI: 0.745

Cites:

Cited by: 12

Related to: 10